Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 1, 2008Results from TAXUS IV and V randomized clinical trials favor DES compared to bare-metal stents
Boston Scientific Corporation (NYSE: BSX) today welcomed favorable outcomes of one- year data from the Company's TAXUS IV and V...
-
Mar 31, 2008At two years, Company's TAXUS® and PROMUS™ Stents demonstrate positive and similar outcomes
Boston Scientific Corporation (NYSE: BSX) today welcomed positive two-year results from Abbott's prospective, randomized (3:1), single...
-
Mar 31, 2008
Boston Scientific Corporation (NYSE: BSX) today announced the sale of Boston Scientific Santa Rosa Corp., formerly known as TriVascular, Inc., to...
-
Mar 29, 2008
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of two-year data from more than 7,000 patients in...
-
Mar 29, 2008
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2...
-
Mar 25, 2008
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the Society for...
-
Mar 11, 2008
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Lehman Brothers Health Care Conference, which is being held March 18...
-
Mar 3, 2008ACUITY® Spiral lead offers flexibility for placement in small, medium and large veins
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of its ACUITY® Spiral left ventricular lead for use with cardiac...
-
Feb 28, 2008
Boston Scientific Corporation (NYSE: BSX) today announced the first European implants of its COGNIS™ cardiac resynchronization therapy...
-
Feb 26, 2008Dr. Jay Schnitzer to join the Company
Boston Scientific Corporation (NYSE: BSX) today announced that Jay J. Schnitzer, M.D., Ph.D. will be joining the Company's Clinical Sciences...
-
Feb 25, 2008Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval for three products in its Cardiac Rhythm...
-
Feb 14, 2008
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Fluid Management and Venous Access businesses to...
-
Feb 12, 2008
Boston Scientific Corporation (NYSE: BSX) today announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent...
-
Feb 11, 2008PROENCY will provide real-world clinical data on the PROMUS™ Stent
Boston Scientific Corporation (NYSE: BSX) today announced that the first patient has been enrolled in its PROENCY (PROMUS™, ENdeavor® and...
-
Feb 4, 2008
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2007, as well as...
-
Feb 4, 2008'Close the Gap' brings together advocates from cardiologists to coaches
Boston Scientific Corporation (NYSE: BSX) today announced the public debut of an educational initiative called "Close the Gap," which is aimed at...
-
Jan 30, 2008
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical...
-
Jan 23, 2008
Boston Scientific (NYSE: BSX) today issued the following statement from Donald S. Baim, M.D., Chief Medical and Scientific Officer, on an article in the New...
-
Jan 23, 2008
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended...
-
Jan 22, 2008
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval for its COGNIS™ cardiac resynchronization therapy defibrillator...
-
Jan 7, 2008
Boston Scientific Corporation (NYSE: BSX) today announced that the Court of Appeals for the Federal Circuit affirmed a District Court ruling which...
-
Jan 7, 2008
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Cardiac Surgery and Vascular Surgery businesses to...
-
Jan 4, 2008Company retains ownership of Pain Management business
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of the controlling interests in its auditory business and...
-
Jan 3, 2008
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the upcoming JP Morgan Health Care Conference, in San Francisco. Paul...
-
Dec 28, 2007
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval for its LIVIAN™ cardiac resynchronization therapy defibrillator...
-
Dec 21, 2007TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) announced today that its TAXUS® Liberte™ paclitaxel-eluting coronary stent system has received...
-
Dec 13, 2007
Boston Scientific Corporation (NYSE: BSX) and Avista Capital Partners, a leading private equity firm, today jointly announced the...
-
Nov 29, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the recommendation of a U.S. Food and Drug Administration (FDA) advisory panel to approve...
-
Nov 28, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the BMO Capital Markets Healthcare Conference, which is being held...
-
Nov 21, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 27...
-
Nov 19, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that an amended agreement has been reached to settle claims associated with a series of...
-
Nov 6, 2007
Boston Scientific Corporation (NYSE: BSX) and GE Healthcare (NYSE: GE) today announced the industry's first patient data...
-
Nov 5, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive agreement for the sale of its Cardiac Surgery and Vascular...
-
Oct 31, 2007
Boston Scientific Corporation (NYSE: BSX) announced today that a jury in U.S. District Court in San Francisco has found that Boston Scientific...
-
Oct 26, 2007Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company
Boston Scientific today announced that Keith Dawkins, M.D., and Takahiro Uchida, M.D., will be joining the Company's Clinical Sciences...
-
Oct 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced positive three-year results from its CABERNET and BEACH carotid artery...
-
Oct 22, 2007TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent
Boston Scientific Corporation (NYSE: BSX) today announced five-year and final follow- up data from its TAXUS IV clinical trial. The...
-
Oct 22, 2007TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels
Boston Scientific Corporation (NYSE: BSX) today announced nine-month data from the pivotal TAXUS ATLAS Small Vessel and Long Lesion...
-
Oct 22, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed results from the SPIRIT III Clinical Trial, which continue to support the...
-
Oct 21, 2007
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,000 patients from its TAXUS ARRIVE 1...
-
Oct 19, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2007, as well as guidance for...
-
Oct 17, 2007Approximately 2,300 positions to be eliminated worldwide
Boston Scientific Corporation (NYSE: BSX) today announced several new initiatives designed to enhance short- and long-term shareholder value,...
-
Oct 16, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...
-
Oct 9, 2007
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of its CONFIENT™ implantable cardioverter defibrillator (ICD). This...
-
Oct 1, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Sep 14, 2007
Boston Scientific Corporation (NYSE: BSX) today released data reflecting experience from the first 15,000 patients(1) monitored wirelessly on the...
-
Sep 6, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Ray Elliott as a Director. Mr. Elliott,...
-
Sep 5, 2007
Boston Scientific Corporation (NYSE: BSX) today announced results from the TAXUS WOMAN study, a gender specific analysis of the...
-
Sep 4, 2007TAXUS® Stent shows no additional very late stent thrombosis
Boston Scientific Corporation (NYSE: BSX) today announced five-year and final results from its TAXUS II clinical trial,...
-
Sep 2, 2007OLYMPIA Launch Phase Results Show Positive Outcomes in Diabetic Patients
Boston Scientific Corporation (NYSE: BSX) today announced one-year results from the European and Intercontinental launch phases...
-
Aug 30, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that three of its subsidiaries, Guidant Corporation, Cardiac Pacemakers Inc. and Guidant...
-
Aug 29, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the European...
-
Aug 28, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bear Stearns 20th Annual Healthcare Conference, which is being held...
-
Aug 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that it has successfully amended its $2 billion revolving line of credit and $5 billion...
-
Aug 16, 2007Transaction Would Advance Company's Plan to Divest Non-Strategic Assets and Strengthen Operating and Financial Performance
Boston Scientific Corporation (NYSE: BSX) today announced its intention to explore the sale of its Cardiac Surgery and Vascular Surgery businesses...
-
Aug 9, 2007BSC to assume sole control of Pain Management business and emerging indications program, Advanced Bionics principals to purchase Auditory business and drug pump program
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an agreement to amend its merger agreement with Advanced Bionics,...
-
Aug 2, 2007Endosurgery group to remain wholly owned by Boston Scientific
Boston Scientific Corporation (NYSE: BSX) today provided an update on its plans to strengthen operating and financial performance as part of its...
-
Jul 24, 2007
Boston Scientific Corporation (NYSE: BSX) today announced its intention to explore the sale of its fluid management business as part of the...
-
Jul 20, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the second quarter ended June 30, 2007, as well as guidance for net...
-
Jul 19, 2007TAXUS PERSEUS clinical program to evaluate platinum enhanced drug-eluting stent
Boston Scientific Corporation (NYSE: BSX) today announced the beginning of clinical trial enrollment in studies evaluating its third-generation...
-
Jul 17, 2007
Boston Scientific Corporation (NYSE: BSX) today announced the successful implantation of the Company's TAXUS® Petal™ Bifurcation...
-
Jul 13, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that an agreement has been reached to settle claims associated with a series of product...
-
Jul 10, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2007...
-
Jul 2, 2007Hardware and software innovations offer new benefits to physicians and patients
Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Precision Plus™ Spinal Cord Stimulation (SCS) System, the world's...
-
Jun 25, 2007
Boston Scientific Corporation (NYSE: BSX) today announced it has signed a definitive agreement to acquire Remon Medical Technologies Inc., a...
-
Jun 21, 2007Deal Follows Successful Four-Year Exclusive Distribution of Prolieve® Thermodilatation System
Boston Scientific Corporation (NYSE: BSX) today announced that it has purchased technology for treating symptomatic benign prostatic hyperplasia...
-
Jun 8, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 28th Annual Healthcare Conference, which is being held June...
-
Jun 4, 2007
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an article in the Journal of American College of Cardiology (JACC)...
-
May 31, 2007Study seeks to confirm the safety and efficacy of systems in routine clinical practice
Boston Scientific Corporation (NYSE: BSX) today announced enrollment of the first patient in the SONOMA post-market approval study of the Company's...
-
May 24, 2007Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease
Boston Scientific Corporation (NYSE: BSX) today announced that it has received CE Mark for its TAXUS® Liberte™ Long...
-
May 22, 2007SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of additional data from the SPIRIT FIRST, II and III...
-
May 22, 2007Study highlights importance of antiplatelet therapy compliance
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of more than 7,000 patients from its ARRIVE...
-
May 22, 2007Trial results report no new stent thrombosis after two years in high-risk patient population
Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS VI clinical trial. The data...
-
May 18, 2007Group supports call for limiting greenhouse gas emissions
Boston Scientific Corporation (NYSE: BSX) today announced that it has joined the U.S. Climate Action Partnership (USCAP). USCAP was formed as a...
-
May 18, 2007Company anticipates broad range of clinical results on endoscopic technologies
Boston Scientific Corporation (NYSE: BSX) today announced that results from several clinical studies designed to determine the safety and efficacy...
-
May 17, 2007Single-operator system allows unprecedented visual access to bile duct
Boston Scientific Corporation (NYSE: BSX) today announced worldwide commercial availability of its SpyGlass™ Direct Visualization System for...
-
May 15, 2007Company to release broad range of clinical data on leading drug-eluting stent portfolio
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual Paris...
-
May 14, 2007More than 23,000 patients now enrolled in TAXUS OLYMPIA registry
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the European and Intercontinental phases (II and III)...
-
May 10, 2007New data provide support for minimally invasive treatment of atrial fibrillation (AF)(1)
Boston Scientific Corporation (NYSE: BSX) today commented on data released on May 9th at the American Association for Thoracic Surgery (AATS)...
-
May 9, 2007
Boston Scientific Corporation (NYSE: BSX) today released data reflecting clinical event notification statistics from the first 10,000 patients(1)...
-
May 8, 2007Reimbursement granted by National Health Insurance System
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS® Express2™ paclitaxel-eluting coronary stent system in Japan....
-
May 3, 2007RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its RENAISSANCE study, which was designed to evaluate...
-
May 1, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice...
-
Apr 26, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its SYNTAX clinical trial. SYNTAX is the first trial...
-
Apr 24, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being...
-
Apr 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2007, as well as guidance for...
-
Apr 17, 2007Product provides enhanced control for accessing desired vessel location
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of the ACUITY® Steerable left...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2007...
-
Apr 16, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that the Company has resolved the deficiencies in the warning letter issued by the U.S....
-
Apr 3, 2007
Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Apr 2, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its MAPS™ clinical trial. The MAPS trial (Matrix And...
-
Mar 26, 2007BTK CHILL study demonstrates high rate of limb protection at one year
Boston Scientific Corporation (NYSE: BSX) today announced excellent one-year results from its Below-The-Knee (BTK) CHILL study,...
-
Mar 25, 2007
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from the TAXUS V In-Stent Restenosis (ISR) trial,...
-
Mar 25, 2007Two-year review of TAXUS Stent safety data presented at ACC
Boston Scientific Corporation (NYSE: BSX) today announced two-year results from its ARRIVE 1 registry and the combined one-year...
-
Mar 24, 2007Results reaffirm strength of Boston Scientific's dual drug-eluting stent program
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of the pivotal SPIRIT III clinical trial, which reaffirmed...
-
Mar 23, 2007
Boston Scientific Corporation (NYSE: BSX) today announced a program designed to improve patient compliance with physician-prescribed anti-platelet...
-
Mar 22, 2007Smallest Dual Chamber System offered in Japan provides enhanced therapies to patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced regulatory approval and market launch in Japan for its VITALITY™ DR implantable...
-
Mar 20, 2007Company to host analyst meeting and symposium on drug-eluting stents
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual...
-
Mar 13, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Lehman Brothers Health Care Conference, which is being held March 19...
-
Mar 12, 2007
Boston Scientific Corporation (NYSE: BSX) today announced that its Board of Directors has authorized management to explore an initial public...